Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 14/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122898 | 0.93 | LMNA (0.52) | KDM4ELMNAHTTNPSR1CYP19A1 | |
| SCHEMBL3123013 | 0.91 | LMNA (0.60) | KDM4ELMNAHTTNPSR1CYP19A1 | |
| SCHEMBL3109112 | 0.85 | CYP19A1 (0.49) | KDM4ELMNAHTTNPSR1CYP19A1 | |
| SCHEMBL3119476 | 0.85 | HTR6 (0.53) | KDM4ECYP19A1HTR6ALKL3MBTL1 | |
| SCHEMBL3110540 | 0.83 | CYP19A1 (0.52) | KDM4ECYP19A1HTR6ALKL3MBTL1 | |
| SCHEMBL3237193 | 0.83 | ALK (0.54) | KDM4ECYP19A1HTR6ALKL3MBTL1 | |
| SCHEMBL3114992 | 0.82 | CYP19A1 (0.51) | KDM4ELMNAHTTNPSR1CYP19A1 | |
| SCHEMBL3118291 | 0.82 | HTR6 (0.55) | KDM4ECYP19A1HTR6ALKL3MBTL1 | |
| SCHEMBL3117229 | 0.81 | CYP19A1 (0.50) | KDM4ECYP19A1HTR6ALKL3MBTL1 | |
| SCHEMBL3117450 | 0.81 | HTR6 (0.53) | KDM4ECYP19A1HTR6ALKL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501957-B2 | Benzimidazole compounds and their use as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-08-06 | — | — | US | disclosed |
| EP-2397471-A1 | Benzimidazole compounds and their use | China Medical University (TW) | 2011-12-21 | — | — | EP | disclosed |
| US-20100179147-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179147-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | H1-3, BAK1, HDAC1 | KDM4E 1152/4885LMNA 2237/4885HTT 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.